Abstract
Vaccination is known to reduce the risk of severe COVID-19, but its effect on post-acute sequelae of COVID-19 (PASC) among patients with systemic autoimmune rheumatic diseases (SARDs) has remained unclear. This study prospectively evaluated 280 SARD patients to determine the impact of vaccination on PASC risk. Results indicate that patients with breakthrough infections experienced significantly more symptom-free days and a substantially lower risk of PASC at 90 days (aOR 0.10) compared to those with non-breakthrough infections. These findings underscore the critical role of vaccination in protecting this vulnerable population from long-term COVID-19 complications.
Introduction
Post-acute sequelae of SARS-CoV-2 (PASC), commonly known as "Long COVID," is a debilitating condition affecting 20–50% of COVID-19 survivors. For individuals with systemic autoimmune rheumatic diseases (SARDs)—such as rheumatoid arthritis or systemic lupus erythematosus—the stakes are particularly high. These patients often utilize immunosuppressive therapies that can dampen vaccine immunogenicity, potentially leaving them more susceptible to both acute severity and the lingering symptoms of PASC. While vaccination has proven effective in the general population, its efficacy in preventing PASC within the SARD community required dedicated investigation.
Methodology
The researchers utilized the RheumCARD cohort, a prospective study within the Mass General Brigham healthcare system. The study followed 280 adult SARD patients who survived an acute COVID-19 infection. Participants were categorized into two groups:
- Breakthrough Infection: Patients who were fully vaccinated at least 14 days prior to their diagnosis (n=116).
- Non-breakthrough Infection: Patients who were unvaccinated or only partially vaccinated at the time of infection (n=164).
The primary outcomes were the odds of PASC at 28 days (CDC definition) and 90 days (WHO definition), analyzed using multivariable logistic regression. Additionally, Restricted Mean Survival Time (RMST) was employed to compare the "symptom-free duration" over a 204-day follow-up period, adjusting for age, sex, race, comorbidities, and specific medications like methotrexate or anti-CD20 antibodies.
Results
The study revealed a stark contrast between the two groups regarding long-term recovery and symptom duration.
Risk Reduction
Vaccination was associated with a significant decrease in the likelihood of developing PASC. At the 28-day mark, the adjusted odds ratio (aOR) was 0.49 (95% CI: 0.29, 0.83). By 90 days, the protection was even more pronounced, with an aOR of 0.10 (95% CI: 0.04, 0.22), representing a 90% reduction in risk for the vaccinated group compared to those with non-breakthrough infections.
Symptom-Free Duration
Over the 204-day follow-up period, patients with breakthrough infections enjoyed an average of 28.9 more symptom-free days (95% CI: 8.83, 48.89; p=0.005) than those in the non-breakthrough group. Furthermore, acute severity was significantly lower in the vaccinated group; only 5% of breakthrough cases required hospitalization, compared to 27% of non-breakthrough cases.
Symptom Profiles
The nature of the acute infection also differed by vaccination status. Breakthrough cases primarily reported upper respiratory symptoms, such as sore throat and congestion. In contrast, non-breakthrough cases were more likely to experience systemic and neurological symptoms, including anosmia (loss of smell), dysgeusia (loss of taste), and joint pain.
Discussion
The findings support the "Initial Response" hypothesis, suggesting that the quality of the body's early immune response to SARS-CoV-2 is a primary determinant of PASC development. Even if a patient's immune response to the vaccine is partially blunted by SARD-related medications, the "priming" provided by vaccination likely facilitates faster viral clearance or prevents the hyper-inflammatory state often associated with long-term symptoms.
Interestingly, the study found that while vaccination is highly effective at preventing the transition to PASC, the severity of symptoms among those who did develop PASC was relatively similar across both groups. This suggests the vaccine's primary benefit in this context is prevention rather than symptom mitigation once PASC has already taken hold.
Limitations
Several limitations should be considered. The study period spanned different viral variants; most breakthrough infections occurred during the Omicron wave, while many non-breakthrough infections occurred earlier in the pandemic. Additionally, the reliance on patient-reported surveys introduces the possibility of recall bias. Finally, the cohort was 82% white and treated at a single academic healthcare system, which may limit generalizability to more diverse populations.
Conclusion
This study provides robust evidence that COVID-19 vaccination significantly reduces the risk of PASC in patients with SARDs. Despite potential blunting of vaccine effectiveness due to immunosuppression, the protective benefits against long-term sequelae remain substantial. These results reinforce the importance of vaccination and boosters for patients with autoimmune conditions to mitigate the long-term burden of the pandemic.
Summary updated